Literature, news and videos pertinent to
The Emily Stone Fail
Ovarian Cancer Patient Advocacy Program
Chemo-Sensitivity Testing for Lung Cancer:
Dr. Robert Nagourney & Ryan Kuper
- Oncology Today with Dr Neil Love— The Evolving Role of PARP Inhibition in the Management of Ovarian Cancer with Dr Shannon Westin
- Open AccessReview— Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
- Study Finds Patients With Rare Ovarian Cancer Develop Chemoresistance | Cancer Therapy Advisor
- FDA Approves Niraparib for Patients With Homologous Recombination Deficiency–Positive Advanced Ovarian Cancer
By The ASCO Post Staff
powered by Surfing Waves
The Emily Stone Fail
Ovarian Cancer Patient Advocacy Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
Federal Tax I.D.: EIN 86-0818253